Boehringer Ingelheim International GmbH
Through scientific innovation and collaboration, Boehringer Ingelheim is committed to discovering and developing novel anti-cancer agents that address unmet needs across a broad range of solid and hematological malignancies. We’re driven by a passion to improve the lives of patients who are battling cancer. Approved agents are for specific NSCLC sub-types and the oncology portfolio is supported by a strong early pipeline. As part of a unique research approach, our active partnering strategy aims to further strengthen our presence in key therapeutic areas.